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Abstract
The capacity of FasL molecules expressed on mela-
noma cells to induce lymphocyte apoptosis contrib-
utes to either antitumor immune response or escape
depending on their expression level. Little is known,
however, about the mechanisms regulating FasL pro-
tein expression. Using the murine B16F10 melanoma
model weakly positive for FasL, we demonstrated that
in vitro treatment with statins, inhibitors of 3-hydroxy-
3-methylgutaryl CoA reductase, enhances membrane
FasL expression. C3 exotoxin and the geranylgeranyl
transferase I inhibitor GGTI-298, but not the farnesyl
transferase inhibitor FTI-277, mimic this effect. The ca-
pacity of GGTI-298 and C3 exotoxin to inhibit RhoA
activity prompted us to investigate the implication of
RhoA in FasL expression. Inhibition of RhoA expres-
sion by small interfering RNA (siRNA) increased mem-
brane FasL expression, whereas overexpression of
constitutively active RhoA following transfection of
RhoAV14 plasmid decreased it. Moreover, the inhibi-
tion of a RhoA downstream effector p160ROCK also
induced this FasL overexpression. We conclude that
the RhoA/ROCK pathway negatively regulates mem-
brane FasL expression in these melanoma cells. Fur-
thermore, we have shown that B16F10 cells, through
the RhoA/ROCK pathway, promote in vitro apoptosis
of Fas-sensitive A20 lymphoma cells. Our results sug-
gest that RhoA/ROCK inhibition could be an interest-
ing target to control FasL expression and lymphocyte
apoptosis induced by melanoma cells.
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Introduction
APO-1/Fas, now called CD95, triggers apoptosis on binding
of its ligand (CD95L/FasL) or specific agonist antibodies [1,2].
Fas have three cysteine-rich extracellular domains and an
intracellular death domain essential for signaling. Two differ-
ent CD95 receptor–induced apoptotic pathways are known
to exist, both leading to subsequent caspase-3 activation
[3]. Widely expressed in both normal and neoplastic cells
[2,4–6], the expression of Fas does not necessarily predict sus-
ceptibility to FasL-induced apoptosis. Fas–FasL interaction is
involved in normal immune development and homeostasis [7,8]
and also in the maintenance of immune privilege in certain or-
gans such as the eye, the central nervous system, and the
testis [9]. Although expressing Fas, cells in these organs show
resistance to Fas-mediated apoptosis. This Fas-resistancemech-
anism has also been described in several tumor models contrib-
uting to the formation and growth of neoplasia [10].
In cancer patients, clinical morbidity and mortality is often
associated with the acquired insensitivity of tumor cells to im-
munologic detection or elimination [11]. FasL expression by
tumor cells represents one possible mechanism responsible for
this immunologic escape, allowing cells to counterattack and
induce apoptosis in Fas-expressing cytotoxic T lymphocytes
and natural killer cells, infiltrating the tumor or the tumor micro-
environment. The expression of FasL on many human tumors,
generally associated with poor prognosis supports this hypoth-
esis. However, the apoptosis-inducing capacity of the FasL
molecules expressed on melanoma cells and, more generally,
the biologic significance of the Fas–FasL implication in human
tumors remains a complex matter of debate [12,13]. In-
deed, conflicting findings have suggested that tumors use
FasL either to counterattack tumor-infiltrating cytotoxic cells
or to trigger a neutrophil-mediated inflammatory response and
tumor rejection [14,15]. Recently, it has been shown that the
effect of FasL may depend on its expression level [14]. At
high levels, FasL triggers tumor rejection by both a potent
neutrophil-mediated local inflammation response and the start
of a T-cell–dependent tumor-specific memory. In contrast, at
low levels, FasL enhances tumor growth by counterattacking
Abbreviations: FTI, farnesyl transferase inhibitor; GGTI, geranylgeranyl transferase inhibitor;
GST, glutathione S-transferase; HMG-CoA, 3-hydroxy-3-methylgutaryl CoA; RT-PCR, reverse
transcription –polymerase chain reaction; siRNA, small interfering RNA
Address all correspondence to: Anne-Franc¸oise Tilkin-Mariame´, Institut Claudius Regaud, 20–24
rue du Pt St Pierre, Toulouse F-31052, France. E-mail: tilkin.anne-francoise@claudiusregaud.fr
1This work was supported by the Institut National de la Sante´ et de la Recherche Me´dicale and by
grants from La ligue contre le cancer re´gion Midi Pyre´ne´es and Institut Claudius Regaud.
2This article refers to supplementary materials, which are designated by Figures W1 and W2
and are available online at www.neoplasia.com.
Received 10 August 2007; Revised 1 October 2007; Accepted 5 October 2007.
Copyright D 2007 Neoplasia Press, Inc. All rights reserved 1522-8002/07/$25.00
DOI 10.1593/neo.07727
Neoplasia . Vol. 9, No. 12, December 2007, pp. 1078–1090 1078
www.neoplasia.com
RESEARCH ARTICLE
antitumor effector lymphocytes. Altogether, these observa-
tions suggest that the increase of FasL expression on tumor
cells could be an interesting goal in cancer immune therapy.
However, in all these tumor models, little is known about the
mechanisms regulating FasL protein expression.
In the present study, we have investigated the capacity of
statins and other Rho protein inhibitors to modulate in vitro
membrane FasL expression. Statins seemed suitable phar-
macological agents with their common use in cardiovascular
disease prevention and recent potential as new anticancer
agents. Based on preclinical studies on several animal tumor
models, such as melanoma, mammary carcinoma, pancre-
atic adenocarcinoma, fibrosarcoma, glioma, neuroblastoma,
and lymphoma, statins have demonstrated antiprolifera-
tive, proapoptotic, antiinvasive, and radiosensitizing proper-
ties [16,17]. However, as we previously reported in the
B16F10murine melanomamodel, statins inhibit Rho GTPases
and modify protein expression on tumor membranes in
a manner favoring a T-cell–dependent tumor-specific im-
mune response. Indeed, statins induced an overexpression
of interferon-g– induced major histocompatibility complex
class I antigens and expression of CD80 and CD86 cos-
timulatory molecules [18]. We chose the B16F10 melanoma
model for its spontaneous weak expression of membrane
FasL [19] to study the effect of statins and other inhibitors of
Rho proteins on FasL expression.
Rho GTPases form a subgroup of the Ras superfamily of
GTP binding proteins that regulate a wide spectrum of cel-
lular functions. Activated Rho GTPases interact with intra-
cellular target proteins or effectors to trigger a wide variety of
cellular responses, including the reorganization of the actin
cytoskeleton, cell cycle progression, cell death, adhesion,
metastasis, and gene transcription [20–28]. Rho proteins
are posttranslationally prenylated by mevalonate-derived
isoprenoid compounds, such as farnesylpyrophosphate
and geranylgeranylpyrophosphate on the C-terminal end of
the protein. The attachment of such isoprenoid residues is
necessary for their anchorage to cell membranes and full
functionality [29]. This isoprenylation can be inhibited by
several inhibitors of the mevalonate pathway such as the
statins or by isoprenyl transferase inhibitors such as farnesyl
transferase inhibitor (FTI) or geranylgeranyl transferase
inhibitor (GGTI).
Here we demonstrate, in the B16F10 tumor model, that
RhoA proteins downregulate membrane FasL expression
and, consequently, the possibility of increasing in vitro this
expression by pharmacological treatments with RhoA inhib-
itors such as statins. Moreover, B16F10 melanoma cells
overexpressing membrane FasL after such treatments were
able to induce in vitro the apoptosis of cocultivated Fas-
sensitive B lymphocytes.
Materials and Methods
Cell Lines
The murine melanoma cell line B16F10 and the murine
B cell lymphoma A20 were maintained by serial passages
in complete culture medium composed of RPMI 1640,
1% L-glutamine, 1% penicillin/streptomycin, and 10% heat-
inactivated fetal calf serum (Gibco BRL, Invitrogen, Cergy-
Pontoise, France).
In Vitro Treatment of Tumor Cells
Tumor cells were treated in vitro by addition of different
components to the complete culture medium. C3 exotoxin
was produced in the laboratory and used at 10 or 20 mg/ml.
FTI-277 was used at 10 or 20 mM (Calbiochem, San Diego,
CA). GGTI-298 was used at 10 or 20 mM (Calbiochem). We
used 5 mM atorvastatin and 5 mM mevalonolactone (Sigma,
St. Louis, MO), 0.5 mM of the p160ROCK inhibitor H1152
(Alexis, Lausen, Switzerland), and 100 mM of the caspase
inhibitor Z-VAD-Fmk (Alexis). Anti-Fas (Jo-2) (50 mg/ml) (BD
Biosciences, San Jose, CA) was used to induce A20 lym-
phoma apoptosis and an Armenian hamster IgG2 (50 mg/ml)
(BD Biosciences) was used as a control. Anti-FasL antibody
(50 mg/ml) (c178) (Santa Cruz Biotechnology, Santa Cruz,
CA) was used to block Fas/FasL interaction and a rabbit IgG
(50 mg/ml) was used as a control.
Flow Cytometry Analysis
FasL and Fas membrane expressions were analyzed us-
ing phycoerythrin- or fluorescein isothiocyanate-conjugated
specific antibodies (BD Biosciences). Apoptosis of Fas-
sensitive A20 lymphoma cells was detected by cell
cycle analysis, according to the protocol of Vindelov and
Christensen [30], and with a fluorescein isothiocyanate-
conjugated anti–active caspase-3 antibody (BD Bioscien-
ces) after permeabilization and fixation of the tumor cells
with the Fix and Perm kit (BD Biosciences). All stainings
were performed according to the manufacturer’s instructions
and were analyzed on a FACS Calibur (Becton-Dickinson,
Franklin Lakes, NJ).
RhoAV14 Overexpression
The coding region of RhoAV14 was subcloned into a
pSG5 vector. An empty pSG5 vector was used as a control.
B16F10 cells, 1  105, were transfected with 2 mg of pSG5-
RhoAV14 (B16F10RhoAV14) construct or empty vector
(B16F10Mock) using Jet PEI (Qbiogen, Illkirch, France).
Small Interfering RNA (siRNA) Treatment
SiRNA against RhoA were designed using the criteria de-
veloped by Simpson et al. [31], synthesized as synthetic oli-
gonucleotides (Eurogentec, Angers, France), and annealed
to form a short double-stranded RNA with a 3V-dithymidine
overhang: siRNA RhoA, 5V–GAA GUC AAG CAU UUC
UGU CdTdT–3. As a siRNA control, we used a nonspecific
control provided by Pharmacon Research (Attica, Greece).
Transfections of siRNA (20 nM) were performed using
Oligofectamine and Opti-MEM media (Invitrogen) according
to the manufacturer’s instructions on cells at 30% to 50%
confluency in 60-mm cell culture dishes followed by a
72-hour incubation period before experiments.
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Immunoblot Analysis of Proteins
Cells were lysed in radioimmune precipitation buffer
(50mMTris, pH 8, 150mMNaCl, 1%Triton X-100, 1%sodium
deoxycholate, 0.1% SDS, 5 mM EDTA, 1 mM dithiothreitol,
10 mM p-nitrophenyl phosphate, 2 mM Na3VO4, 20 mM NaF,
and 1 protease inhibitor mixture) for 30 minutes on ice, and
cleared by centrifugation (14,000 rpm for 10 minutes). Protein
concentration was determined using the bicinchoninic acid
assay (Pierce, Rockford, IL). Proteins were resolved on
SDS-PAGE with the appropriate acrylamide concentration
(10%). Detections were made using antibodies against FasL
(c178), RhoA (119), Rap1a (121), and unprenylated Rap1a
(C-17) (Santa Cruz Biotechnology); Hdj2 antibody (KA2A5.6)
was obtained from NeoMarkers (Interchim, Montluc¸on,
France) and antiactin was from Chemicon (Billerica, MA).
Reverse Transcription–Polymerase Chain Reaction
(RT-PCR) Detection of FasL mRNA Transcripts
The expression of FasL mRNA was analyzed by RT-
PCR. Total RNA was isolated using RNA easy kit (Qiagen,
Courtaboeuf, France) according to the manufacturer’s in-
structions. One microgram of total RNA was used for first-
strand cDNA synthesis in iScript cDNA Synthesis Kit
(Bio-Rad, Marnes la Coquette, France). Then, RT-PCR
was conducted as previously described [19]; briefly, FasL
cDNA were amplified by 35 cycles of PCR using the intron-
spanning primers described by Ryan et al. [19]: forward
5V–CGGTG-GTATITITCATGGTTCTGG–3V and reverse 5V–
CTTGTGGTTTAGGGGCTGGTT-GTT–3V (380) and com-
pared to b-actin. PCR products were resolved on a 2%
agarose gel and visualized by ethidium bromide staining.
RhoA Activity Assay
RhoA activity was assayed using the RhoA activation
assay of Ren and Schwartz [32]. Briefly, the Rho binding
domain of rothekin (TRBD), an effector of Rho proteins that
selectively binds to the GTP-loaded form, was expressed as
a recombinant fusion with glutathione S-transferase (GST) in
Escherichia coli and purified through binding to glutathione–
Sepharose beads. At various times after exposure, cells were
lysed by scraping on ice and by vigorous mixing in lysis buffer
(50 mM Tris–HCl, pH 7.5, 500 mM NaCl, 10 mM MgCl2, 1%
Triton X-100, 10 mM dithiothreitol, 10 mM p-nitrophenyl phos-
phate, 2 mM Na3VO4, 20 mM NaF, and 1 protease inhibi-
tor mixture (Sigma)). After preclearing by centrifugation
(12,500 rpm for 5 minutes), the lysates were combined with
30 ml GST–TRBD beads and rotated for 45 minutes at 4jC.
An aliquot from each lysate was removed as a control for
equivalent input into the assay. Beads were washed twice
with ice-cold wash buffer (50 mM Tris–HCl, pH 7.5, 500 mM
NaCl, 10 mM MgCl2, and 1% Triton X-100). Bound proteins
were eluted from the beads with SDS-PAGE sample buffer at
95jC. RhoA proteins were analyzed by immunoblot.
Visualization of Actin Cytoskeleton By
Fluorescence Microscopy
At day 0, B16F10 cells were seeded onto glass cover-
slips in six-well plates to obtain 60% confluence on day 2. On
day 1, the cells were treated for 24 hours with 0.5 mM H1152.
On day 2, cells were fixed with 3% paraformaldehyde/PBS
for 20 minutes and then permeabilized with 0.1% Triton
X-100/PBS for 5 minutes. To visualize the actin fibers,
the coverslips were incubated with tetramethylrhodamine
isothiocyanate-labeled phalloidin (Molecular Probes, Invitro-
gen) for 30 minutes at room temperature. The cells were
viewed on a Zeiss Axiophot microscope (Zeiss, New York, NY)
and pictures were taken with a Princeton Camera (Princeton,
Scientific Instruments, Monmouth Junction, NJ).
Cocultures
A20 cells, 1  105, were cocultivated in complete culture
mediumwith 1 to 3 105 B16F10 melanoma cells or with 1
105 B16F10-transfected or inhibitor-treated cells. The per-
centage (%) of A20 cells in the sub–G1-peak (% subG1) and
the percentage of A20 cells expressing the caspase-3 active
form (% active caspase-3) was analyzed by flow cytometry
after 24 and 72 hours of coculture, respectively.
Statistical Analysis
All experiments were performed three or six times.
Results are expressed as mean ± SEM and were analyzed
by Student’s t test (differences were considered significant at
a P value of < .05).
Results
Atorvastatin Upregulates FasL Expression on the B16F10
Cell Membrane
We previously described that several pharmacological
inhibitors of protein prenylation could modulate melanoma
membrane expression of molecules implicated in the im-
mune response [18]. In the mevalonate pathway, statins are
inhibitors of 3-hydroxy-3-methylgutaryl CoA (HMG-CoA) re-
ductase and thus of protein prenylation. We tested the role of
atorvastatin on FasL expression in melanoma cells using the
weakly FasL-positive murine melanoma cell line B16F10
[19]. Membrane and total FasL expressions were measured
by cytofluorometric and Western blot analysis, respectively.
Treatment of B16F10 cells for 48 hours with atorvastatin
(5 mM) enhanced the percentage of melanoma cells express-
ing FasL on the membrane (Figure 1 A) compared to the
untreated control. This effect was completely reversed by
mevalonate (5 mM), the first product of HMG-CoA reductase
(Figure 1 A). The analysis of three independent experiments
confirmed that statin treatment statistically increases the
percentage of FasL+ B16F10 cells (P < .05) (Figure 1 B).
To determine whether total FasL protein is also altered by
statin treatment, we treated B16F10 cells for 48 hours with
atorvastatin and/or mevalonate and analyzed whole cell ly-
sates for FasL expression usingWestern blot. Results showed
no difference in total FasL expression between statin-treated
and control cells (Figure 1 C), showing that statin activity is
restricted to membrane FasL localization.
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Overall, these results show that statin increases membrane
FasL expression in the murine B16F10 melanoma model.
Inhibition of Protein Geranylgeranylation by GGTI-298
Increases FasL Expression on the B16F10 Cell Membrane
The mevalonate-derived isoprenoid compounds farne-
sylpyrophosphate and geranylgeranylpyrophosphate are
transferred on target proteins such as Rho by the specific en-
zymes farnesyl transferase and geranylgeranyl transferase.
These posttranslational modifications enable the functional
activity of isoprenylated Rho proteins. However, this isopren-
ylation can be inhibited by the specific inhibitors FTI and
GGTI, leading to loss of anchorage and activity of the Rho
proteins. We therefore used either FTI-277 or GGTI-298 to
test whether inhibition of protein isoprenylation also induces
an increase in membrane FasL expression. Firstly, we en-
sured that these two prenyl transferase inhibitors prevented
protein isoprenylation with weak toxicity using our culture
conditions. Indeed as expected, FTI-277 treatment at 10 mM
inhibited the exclusive farnesylation of Hdj2 (Figure 2 C),
but had no effect on the exclusive geranylgeranylation of
Rap1a [34]. On the contrary, GGTI-298 at 10 mM prevented
the prenylation of Rap1a but not of Hdj2 (Figure 2 F). We
then treated the B16F10 cells for 48 hours with FTI-277 or
GGTI-298 at 10 or 20 mM before cytofluorometry analysis of
membrane FasL expression. As shown in Figure 2, D and E,
GGTI-298, but not FTI-277 (Figure 2, A and B), increased the
percentage of B16F10 cells expressing membrane FasL to a
similar extent as that noted with atorvastatin (Figure 1 A). We
obtained similar results in three independent experiments
(Figure 2, B and E ), confirming a statistical increase in FasL+
B16F10 cells after GGTI-298 treatment (P < .01).
Together, these results show that geranylgeranyl trans-
ferase inhibition enhances membrane FasL expression in
B16F10 melanoma cells.
RhoA/ROCK Pathway Negatively Regulates Membrane
FasL Expression in B16F10 Melanoma Cells
As indicated previously, GGTI-298 efficiently prevents
geranylgeranylation of several proteins, including the Rho
GTPases [34,35]. We therefore tested the hypothesis that
RhoA, the most characterized Rho GTPase, is involved in
the regulation of FasL. We firstly ensured that GGTI-298
treatment impaired RhoA activation in the B16F10 cells in
our culture conditions. Indeed, using a GST Rho binding do-
main pull-down assay [36], we detected a strong inhibition of
the GTP-bound RhoA in the B16F10 cells treated with 10 mM
GGTI-298 compared to untreated cells (Figure 3 A). This re-
sult suggests that GGTI-298 could enhance membrane FasL
expression through the inhibition of Rho protein activation.
The ADP-ribosyl transferase C3 toxin of Clostridium botuli-
num can also inhibit the activation of Rho proteins [37]. We
therefore checked the occurrence of ADP ribosylation of RhoA
proteins in our culture conditions (Figure 3 B) and tested the
effects of this toxin on membrane FasL expression. As shown
in Figure 3 C, treatment of B16F10 cells with C3 exotoxin
significantly increased (P < .01) the percentage of membrane
FasL+ cells in a dose-dependent manner. Together, these re-
sults suggest that Rho proteins negatively regulatemembrane
FasL expression in these melanoma cells. To confirm the in-
volvement of RhoA proteins in the regulation of FasL expres-
sion, we analyzed the effect of both RhoA-specific siRNA
and an expression vector for constitutively active RhoA
(RhoAV14). As shown in Figure 3 D, the transfection of
RhoA-specific siRNA simultaneously resulted in a strong inhi-
bition of RhoA expression as detected by Western blot and an
upregulation of membrane FasL expression as detected by
cytofluorometry. Both detections were made 72 hours after the
transfection. This increase in FasL+ melanoma cells was
statistically significant with a P < .01. Furthermore, these trans-
fected cells were simultaneously used to detect the total FasL
expression by Western blot and the FasL mRNA level by
RT-PCR. As also illustrated in Figure 3 D, the transfection of
RhoA-specific siRNA affected neither total FasL protein ex-
pression nor FasL mRNA level. Conversely, transfection of the
pSG5-RhoAV14 vector led to a simultaneous increase in RhoA
expression and a statistically significant (P < .05) decrease in
B16F10 cells expressing membrane FasL.
Together, results from these two experiments show that
RhoA negatively regulates membrane FasL expression on
these melanoma cells. The critical role of RhoA in the reg-
ulation of FasL expression prompted us to investigate down-
stream effectors of RhoA with possible involvement in this
regulation. One such candidate effector molecule is the mul-
tidomain protein p160ROCK containing a serine/threonine
kinase domain, a pleckstrin homology domain, cysteine-rich
regions, and an amphipathic alpha-helical region. The ki-
nase activity of p160ROCK is required to regulate events
downstream of RhoA and particularly actin polymerization.
We investigated the implication of p160ROCK in FasL mem-
brane expression using the specific p160ROCK inhibitor
H1152. As shown in Figure 4 A, a 24-hour treatment with
0.5 mM H1152 decreased stress–fiber formation, suggesting
that, in our culture conditions, this treatment efficiently in-
hibited p160ROCK activity. In these same conditions, we
therefore tested the effect of H1152 on membrane FasL ex-
pression. As shown in Figure 4 B, B16F10 cells treated with
0.5 mMH1152 showed an overexpression of membrane FasL
compared to untreated cells. This indicates an implication of
the RhoA effector protein p160ROCK in the RhoA-dependent
regulation of membrane FasL expression.
Altogether, these data support the proposition that the
RhoA/ROCK pathway is specifically involved in the control of
FasL expression on B16F10 cell membranes.
Figure 1. Statins upregulate FasL expression on B16F10 cell membrane. B16F10 melanoma cells were incubated with atorvastatin (5 M), mevalonate (5 mM), or
both for 48 hours. Cells were harvested and FasL was immunodetected by flow cytometry using a phycoerythrin-conjugated murine FasL monoclonal antibody. The
percentage of FasL-positive cells (FasL+ cells (%)) is indicated (A). This percentage of FasL-positive cells was also analyzed in three independent experiments (B).
A statistically significant increase (P < .05) is illustrated by an asterisk (*). Similarly treated B16F10 cells were lysed and immunoblotted with murine anti-FasL
antibody for total FasL protein detection. Data from one representative of three independent experiments are shown (C).
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Apoptosis of A20 Lymphoma Cells Induced by Coculture
with B16F10 Melanoma Cells
To study the in vitro biologic function of membrane-
expressed FasL, we tested the capacity of B16F10 cells to
induce the apoptosis of Fas-positive murine A20 lymphoma
cells. First, we checked the sensitivity of A20 cells to apop-
tosis by the Fas/FasL pathway in our culture conditions. We
treated the A20 cells with an anti-Fas antibody (clone Jo-2)
(50 mg/ml) and measured the occurrence of apoptosis by
cytofluorometric analysis of the cell cycle and expression of
active caspase-3. As expected, treatment of A20 cells with
anti-Fas antibody increased the percentage of cells express-
ing the active caspase-3 form and the percentage of cells in
the sub–G1-peak, compared to cells treated with the IgG2
Figure 2. Inhibition of protein geranylgeranylation by GGTI-298 increases FasL expression on B16F10 cell membrane. B16F10 cells were incubated with FTI-277
(10 and 20 M) or GGTI-298 (10 and 20 M) for 48 hours. Cells were harvested and FasL was immunodetected by flow cytometry. The percentage of FasL-positive
cells is indicated (A and D). Histograms illustrating this percentage of FasL+ cells analyzed by flow cytometry from three independent experiments, using increasing
doses of FTI-277 (0, 10, and 20 M) (B) or GGTI-298 (0, 10, and 20 M) (E). A statistically significant increase (P < .01) is illustrated by double asterisks (**).
Similarly treated B16F10 cells were also analyzed and immunoblotted with Rap1a or Hdj2 antibody to confirm farnesyl transferase inhibition (C) and geranylgeranyl
transferase inhibition (F) obtained by FTI-277 (10 M) or GGTI-298 (10 M) treatment, respectively.
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control antibody (Figure W1). To test the ability of B16F10
cells to induce lymphocyte apoptosis, we cocultured A20
lymphoma cells with a growing number of B16F10 cells for
72 hours and measured the occurrence of apoptosis as pre-
viously described. We detected a B16F10 dose-dependent
increase in A20 cells in the sub–G1-peak (Figure W2).
Moreover, as shown in Figure 5 A, the percentage of A20
cells expressing the active form of caspase-3 strongly in-
creased (8-fold increase) following 24 hours of A20 and
B16F10 coculture. We obtained similar results in three
Figure 3. RhoA negatively regulates membrane FasL expression on B16F10 melanoma cells. (A) B16F10 cells were incubated with GGTI-298 (10 M) for 48 hours
and RhoA activity was analyzed by TRBD assay as described in the Materials and Methods section. (B) B16F10 cells were incubated with C3 exoenzyme (10 g/
ml) for 48 hours. Untreated and treated cells were lysed and immunoblotted with anti-RhoA antibody to test RhoA-ADP ribosylation as described in the Materials
and Methods section. (C) B16F10 cells were treated with C3 exoenzyme (10 and 20 g/ml). Cells were harvested and FasL was immunodetected by flow
cytometry. The percentage of FasL-positive cells (FasL+ cells (%)) was analyzed; data shown are mean values of three independent and reproducible experiments.
A statistically significant increase (P < .01) is illustrated by double asterisks (**). (D) B16F10 cells were transfected either with scramble siRNA or with RhoA-
specific siRNA (SiRhoA) and analyzed after 72 hours to evaluate by cytofluorometry the percentage of FasL-positive cells. The scramble siRNA contains a
disorganized sequence of the same nucleotides and is therefore unable to cut the target RNA sequence. Again, data shown are mean values of three independent
and reproducible experiments. A statistically significant increase (P < .01) is illustrated by double asterisks (**). Similarly transfected cells were also lysed and
immunoblotted with either anti-RhoA antibody or anti-FasL antibody and compared to actin expression to check the efficiency of the RhoA-specific siRNA and the
total FasL protein expression. RNA of these transfected cells were also used to compare their FasL mRNA levels by RT-PCR, as described in the Materials and
Methods section. (E) B16F10 cells were also transfected with a pSG5 empty vector (Mock) or with a pSG5-RhoAV14 vector encoding for the active form of RhoA
(RhoAV14). After 72 hours, membrane-expressed FasL was immunodetected by flow cytometry. The percentages of FasL-positive cells are shown as mean values
of three independent and reproducible experiments. A statistically significant decrease (P < .05) is illustrated by an asterisk (*). These cells were also lysed and
immunoblotted with anti-RhoA antibody to test the efficiency of the transfected pSG5-RhoAV14 vector to increase RhoA expression in B16F10 cells.
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independent experiments (Figure 5 B ), confirming statisti-
cally significant increases in A20 cells expressing the active
form of caspase-3 after coculture with growing ratios of
B16F10 to A20 cells. To confirm the implication of the Fas
signaling pathway and Fas/FasL interaction in these events,
we added either a caspase inhibitor (Z-VAD-Fmk) or a block-
ing anti-FasL antibody (c178) to the coculture medium. The
results presented on Figure 5 C show that both the caspase
inhibitor and the FasL blocking antibody inhibited A20 apop-
tosis induced by B16F10 coculture, as illustrated by the
decrease in the active form of caspase-3, not observed in
the control culture conditions.
Collectively, these results show that membrane FasL on
B16F10 melanoma cells induces apoptosis of A20 lymphoma
cells by the Fas signaling pathway in coculture experiments.
Transfection of B16F10 Cells with RhoA-Specific siRNA
or Activated RhoA Modifies Their Efficiency to Induce
Apoptosis of Cocultivated Cells
Having shown that RhoA protein negatively regulates
membrane FasL expression in B16F10 cells and that in
coculture these cells induce apoptosis of Fas-sensitive A20
cells by the Fas signaling pathway, we now wished to check if
modulating the level of membrane FasL on B16F10 cells
could modify the induction of apoptosis in cocultivated A20
cells. We therefore cocultivated A20 cells with B16F10
melanoma cells previously transfected with either the
pSG5 empty vector (B16F10Mock) or the RhoAV14 pSG5
vector (B16F10RhoAV14), which decrease FasL expression
as shown in Figure 3 E. We then analyzed apoptosis through
caspase-3 activity. As shown in Figure 6 A, the level of A20
apoptosis significantly decreased (P < .01) when A20 cells
were cocultivated with B16F10RhoAV14 cells compared to
B16F10Mock. Conversely, A20 cells were also cocultivated
with B16F10 cells previously transfected with control (scram-
ble) or RhoA-specific siRNA and the level of the active form
of caspase-3 was evaluated. As shown in Figure 6 B, we
observed an increase in the level of apoptosis in A20 cells on
cocultivation with SiRhoA-transfected B16F10 melanoma
cells (B16F10SiRhoA) as compared with B16F10 cells trans-
fected with the scramble plasmid (B16F10Sc). Moreover, the
addition of a blocking anti-FasL antibody (c178) in the culture
medium inhibited the increase in caspase-3 activity observed
in these A20 cells compared to control culture conditions
(IgG control). These data suggest that the increase in A20
apoptosis is associated with an increase in available mem-
brane FasL molecules.
Finally, we tested the implication of p160ROCKmolecules
in this apoptosis induction mechanism. We cocultivated A20
cells with B16F10 cells either untreated or previously pre-
treated with the p160ROCK inhibitor (H1152, 0.5 mM). As
shown in Figure 6 C, H1152 pretreatment significantly (P <
.05) enhanced the capacity of B16F10 cells to induce apop-
tosis, as illustrated by the increase in the active form of
caspase-3. Moreover, addition of the blocking anti-FasL anti-
body (c178) in the culture medium significantly (P < .01) in-
hibited this effect.
Figure 4. Inhibition of p160ROCK increases FasL expression on B16F10 cell
membrane. (A) B16F10 cells were seeded onto glass coverslips in six-well
plates to obtain 60% confluence on day 2. On day 1, cells were treated with
0.5 M H1152 for 24 hours. After treatment, actin fibers were visualized by
tetramethylrhodamine isothiocyanate-labeled phaloidin. Cells were viewed
under a Zeiss Axiophot microscope ( 630), and pictures taken with a
Princeton Camera. (B) B16F10 cells were incubated with 0.5 M H1152 for
24 hours. Cells were harvested and FasL was immunodetected by flow
cytometry. Histograms illustrating the percentage of FasL+ cells analyzed by
flow cytometry from three independent experiments. A statistically significant
increase (P < .01) is illustrated by double asterisks (**).
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Altogether, these data demonstrate that membrane FasL
molecules are responsible for the apoptosis induced by
B16F10 melanoma cells in A20 lymphoma target cells.
Furthermore, as RhoA/ROCK negatively regulates mem-
brane FasL expression on these melanoma cells, their
inhibition increased the apoptosis of A20 cells, whereas the
overexpression of activated RhoA reduced A20 apoptosis.
RhoA or p160ROCK may therefore represent interesting
target molecules to modulate the antitumor immune re-
sponse through membrane FasL expression.
Figure 5. Apoptosis induced by Fas/FasL pathway of A20 lymphoma cocultivated with B16F10 melanoma cells. (A) A total of 1  105 A20 cells were cultivated
alone or with 3  105 of B16F10 melanoma cells for 24 hours and the expression of the active form of caspase-3 was evaluated by cytofluorometry with a specific
antibody in permeabilized A20 cells. Data shown are from one representative of three independent and reproducible experiments. (B) A total of 1  105 A20 cells
were cultivated alone or with increasing numbers of B16F10 melanoma cells (1  105; 3  105) for 24 hours and expression of the active form caspase-3 was
evaluated by cytofluorometry. Data shown are mean values of three independent experiments. A statistically significant increase (P < .01) is illustrated by double
asterisks (**). (C) A total of 1  105 A20 cells were also cultivated for 24 hours alone or with 1  105 B16F10 cells, in the absence (medium) or the presence of
100 M caspase inhibitor Z-VAD-Fmk (Z-VAD-Fmk). Medium corresponds to the normal culture medium containing 1% DMSO to be in the same conditions as
those required by the Z-VAD-Fmk inhibitor. Coculture experiments were also carried out with blocking anti-FasL antibody (c178) at 50 g/ml (anti-FasL antibody) or
matched isotype control (IgG). IgG corresponds to the normal culture medium containing 50 g/ml of a rabbit IgG used as control for the anti-FasL antibody. Data
shown are mean values of three independent experiments. Statistically significant decreases (P < .05) induced by the inhibitor or the blocking antibody are
illustrated by an asterisk (*).
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Figure 6. RhoA negatively regulates FasL-induced apoptosis of A20 cells cocultivated with B16F10 melanoma cells. (A) A20 lymphoma cells (1  105) were
cultivated for 24 hours, either alone or with 1  105 B16F10 cells, transfected with either pSG5 empty vector (B16F10Mock) or pSG5-RhoAV14 vector
(B16F10RhoAV14). The percentage of A20 cells expressing the active form of caspase-3 (% active caspase-3) was analyzed by flow cytometry. (B) A20 lymphoma
cells (1  105) were also cocultivated for 24 hours either alone or with 1  105 B16F10 cells transfected with a control siRNA (B16F10Sc) or a RhoA-specific siRNA
(B16F10SiRhoA). (C) A20 cells (1  105) were also cocultivated for 24 hours either alone or with 1  105 B16F10 cells treated or not by ROCK inhibitor (0.5 M
H1152). These cultures (B) and (C) were made both in a control medium containing an IgG isotype control (IgG) and in a medium containing a blocking anti-FasL
antibody at 50 g/ml (antibody anti-FasL). The percentage of A20 cells expressing the active form of caspase-3 was analyzed by flow cytometry. Data shown are
from one experiment representative of three. Statistically significant increases or decreases of A20 cells expressing the active form of caspase-3 are illustrated by
an asterisk (*) (P < .05) or double asterisks (**) (P < .01).
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Discussion
Malignant cells possess several strategies to escape im-
mune surveillance such as low-level expression of target
antigens recognized by cytotoxic T lymphocytes [38], a de-
crease or loss of the human leukocyte antigen class I or class
II molecule expression required for antigen presentation
[39,40], and suppression of immune cell function by secret-
ing factors such as IL-10 or transforming growth factor–b
[41]. Interestingly, some tumor cells have also developed an-
other strategy named the Fas-counterattack mechanism
[42], whereby loss of Fas expression or function and the ab-
errant expression of FasL by tumor cells contribute to their
evasion of host immune surveillance by triggering apoptosis
of Fas-positive antitumor effector lymphocytes [43,44].
FasL expression has been described on some tumor
models [19]; however, few studies have focused on the reg-
ulation of expression levels. In this in vitro study, we have
shown that expression of FasL on themembranes of B16F10
murine melanoma cells [19] is strongly increased by treat-
ment with the HMG-CoA reductase inhibitor atorvastatin.
However, we observed no change in the level of total FasL
protein, indicating that atorvastatin interferes with membrane
localization of FasL, either modifying its stability or traffick-
ing to the cell surface. The upregulation of membrane FasL
expression induced by atorvastatin is reversed by coincuba-
tion with mevalonate, suggesting the involvement of isopren-
oid compounds from the cholesterol pathway downstream
of mevalonate. An inhibitor of protein geranylgeranylation
(GGTI-298) but not of protein farnesylation (FTI-277) can
also upregulate FasL expression, supporting the role of a
protein modified by geranylgeranylation in this regulation.
We also observed an upregulation of membrane FasL in the
presence of C. botulinum C3 exotoxin, a selective inhibitor of
Rho protein activation. Overall, these results indicate a close
relationship between the upregulation of membrane FasL
and the Rho inhibition. Transfection experiments with either
a vector expressing an active form of RhoA (RhoAV14)
or siRNA against RhoA confirmed a role of this small G pro-
tein in the control of FasL expression. Inhibition of RhoA by
siRNA increased FasL expression in B16F10 cells, whereas
constitutively active RhoA decreased it. These data show
that RhoA negatively regulates membrane FasL expression
in B16F10 cells.
Previous studies have shown that the small GTPases
RhoA or Rac1 regulate transcription of FasL in different cell
lines such as Jurkat leukemia cells or NIH-3T3 fibroblast
[45,46]. However, to our knowledge, this study is the first to
implicate RhoA in the negative regulation of membrane FasL
expression, showing no correlation with the total level of FasL
protein. Rho GTPases are involved in different cellular mech-
anisms such as the regulation of transcription, cell motility,
adhesion, or membrane trafficking. Bossi and Griffiths [47]
Figure 7. Schematic representation of the effects of RhoA/ROCK signaling pathway inhibition on membrane FasL expression and lymphocytes apoptosis. In vitro
treatments of B16F10 melanoma cells with inhibitors of the RhoA/ROCK pathway increase the membrane FasL expression on these treated tumor cells. This
(over)expression promoted the apoptosis of Fas-sensitive lymphocytes.
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demonstrated the storage of newly synthesized FasL in
specialized secretory lysosomes in CD4+ and CD8+ T lym-
phocytes and natural killer cells and showed that polarized
degranulation controls the delivery of FasL to the cell surface.
More recently, studies in tumor cells and, more particularly,
melanoma cells have demonstrated the storage of preformed
FasL in lysosomal microvesicles, able to traffic to the cell
surface [48,49]. These observations could explain why RhoA
negatively regulates membrane FasL expression. Indeed,
Nishimura et al. [50] demonstrated that, by regulating both
cytoskeletal microtubule organization and the actin cytoskel-
eton, the RhoA/ROCK–mediated signaling pathway is in-
volved in the intracellular membrane dynamics of lysosomes.
In this model, RhoA/ROCK pathway regulates the traffic and
the localization of lysosomes in the cytoplasm and the cell
membrane, possibly explaining themodulation ofmembrane-
expressed FasL without modification of the total level of this
ligand. The upregulation of membrane FasL expression in
B16F10 cells treated with either the ROCK inhibitor HT115 or
RhoA SiRNA strongly support the hypothesis that an active
RhoA/ROCK pathway disrupts vesicle trafficking to the cell
surface thereby decreasing membrane FasL expression.
The biologic significance of FasL expressed on tumor
cells, still needs to be elucidated. In vitro, membrane-
expressed FasL favor tumor immune evasion through apop-
tosis of cocultivated lymphocytes. Here, we demonstrated
that FasL-expressing B16F10 cells can induce apoptosis of
Fas-sensitive A20 B lymphoma cells. Growing numbers of
B16F10 melanoma cells cocultured with A20 cells induce
increased A20 cell death, associated with an upregulation of
the active form of caspase-3. Hetz et al. [51] demonstrated
the association of upregulated caspase-3 activity and Fas/
FasL–dependent A20 apoptosis and identified this specific
caspase as a marker of apoptosis in this lymphoma cell. The
increased caspase-3 activation seen in A20 cocultivated with
B16F10 must be dependent on the binding of FasL ex-
pressed on B16F10 membrane with the Fas molecule on
A20 cells. This hypothesis is further supported by the fact
that B16F10 cells transfected with constitutively active
RhoA, which decreases membrane FasL expression, induce
A20 apoptosis less efficiently than B16F10 cells transfected
with the empty vector. Conversely, the in vivo significance of
FasL molecules expressed on tumor cells remains ambigu-
ous. On the one hand, downregulation of FasL expression in
colon cancer cells was recently shown to result in an in-
creased antitumor immune response and decreased tumor
formation in vivo, providing functional evidence in favor of the
Fas counterattack as a mechanism of tumor immune evasion
[52,53]. Conversely, several studies have suggested that
FasL expressed on tumor cells did not favor in vivo tumor
evasion [54]. Interestingly, Wada et al. [14] demonstrated
that the level of FasL expression on B16F10 cells is crucial
for their in vivo behavior. Indeed, B16F10 cells expressing a
high level of FasL induce tumor rejection associated with an
inflammatory response, whereas B16F10 expressing a low
level of FasL induce enhanced tumor growth by a counter-
attack mechanism without activating the protective inflam-
matory response.
Our study in B16F10 melanoma cells provides evidence
that in vitro lymphocyte apoptosis, induced throughmembrane-
expressed FasL molecules, may be negatively regulated by
the RhoA/ROCK pathway, as summarized in Figure 7. Ac-
cording to the enhanced tumor rejection of B16F10 cells ex-
pressing high levels of FasL [14], inhibitors of the RhoA/
ROCK pathway could be interesting pharmacological agents
to reduce tumor growth. This work, therefore, provides fur-
ther support for our previous findings suggesting an involve-
ment of Rho GTPases in mechanisms by which tumors either
escape or modulate the antitumor immune response [18]. Our
works identify RhoA protein as a new target for therapeutic
strategies on melanoma treatment.
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